Skip to main content
SpringerLink
Log in

Gene-expression risk scores cost effective to guide NSCLC chemo

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Roth JA, et al. Cost-Effectiveness of the Pervenio(TM) Risk-Score (RS) Assay in Early-Stage Non-Small Cell Lung Cancer. 15th World Conference on Lung Cancer : abstr. P1.06-050, 27 Oct 2013.

  2. Wong KM, et al. A cost-effectiveness analysis of the 15-gene expression signature in guiding adjuvant chemotherapy in early stage non-small cell lung cancer based on the JBR.10 trial. 15th World Conference on Lung Cancer : abstr. MO08.08, 27 Oct 2013.

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gene-expression risk scores cost effective to guide NSCLC chemo. PharmacoEcon Outcomes News 693, 6 (2013). https://doi.org/10.1007/s40274-013-0932-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0932-2

Search

Navigation